We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
June 5, 2023
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
February 3, 2023
The theme for this year’s World Cancer Day is Close the Care Gap. Health equity is a pillar of our work at Imagia Canexia Health. So today our Chief Medical Officer, Dr. David Huntsman, is opening the conversation to showcase how our community-centered approach to cancer care is improving access to genomic-driven cancer care for all.
December 7, 2022
Read about the history of the Human Genome Project.
November 15, 2022
The entire month of November is Lung Cancer Awareness Month. ICH is opening up the conversation to showcase how our distributed data-driven approach is improving health equity in lung cancer cures.
August 30, 2022
NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting
June 15, 2022
Leveraging the Imagia Canexia Health Insights Platform (ICHIP), now Canadian oncologists can deliver precision cancer treatments to patients no matter where they live.
May 26, 2022
Funari appointment helms Imagia Canexia Health with a distinguished biology and data science leader to further the company’s precision cancer care mission.
May 19, 2022
Health is becoming digital health, encompassing everything from electronic patient records to telemedicine and mobile health — spurred on by the pandemic. But the next evolution will involve artificial intelligence. While the potential of AI is enormous, there are still a number of challenges to delivering impactful solutions for clinical adoption.
Every Imagia Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.